News

ODU hires Associate VP for Innovation & Commercialization

Kevin Leslie will be Old Dominion University’s first associate vice president for innovation and commercialization, the Norfolk-based university announced Friday.

Leslie will improve ODU’s technology transfer operation to better identify, develop and market faculty, staff and student intellectual property and startups. He also will lead federal and other grant applications related to innovation and ecosystem building.

“Dr. Leslie will take ODU’s innovation and commercialization activities to the next level of success, as appropriate for an R1 institution,” Morris Foster, ODU vice president for research, said in a statement. “ODU will expand its role as Hampton Roads’ academic research and innovation leader.”

For the past two years, Leslie has served as the inaugural executive director of the Hampton Roads Biomedical Research Consortium, a state-sponsored partnership between ODU, Eastern Virginia Medical School, Norfolk State University and Sentara Healthcare to advance regional health equity and bio-health innovation. He worked with regional leadership to deploy $22 million in capital and operating funds, develop and implement strategic plans and build shared research infrastructure and resources.

“Building the Hampton Roads Biomedical Research Consortium helped me gain a deep understanding of the region and its institutions,” Leslie said in a statement. “As ODU’s role in Hampton Roads and the commonwealth continues to grow, I look forward to building on that knowledge to accelerate the translation of ideas from its labs and classrooms out into the world.”

Before leading the HRBRC, Leslie was associate director of Virginia Commonwealth University Ventures and helped lead Richmond’s Health Innovation Consortium, a public-private platform to support novel health care technologies.

Leslie holds bachelor’s and master’s degrees in biology from William & Mary. He has a doctorate in integrated life sciences from VCU.

He is a member of the Civic Leadership Institute’s 2023 Executive Program class and has served as adjunct faculty for the National Science Foundation Innovation Corps (I-Corps) program.

In his role, Leslie will work closely with Sarah Jane Kirkland, who ODU named associate vice president for corporate partnerships in December 2022.

 

Learn more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin